Observe what drugs do to living human tissue on a chip. The screening application layer that sits on every organ-on-chip platform - now mandated by FDA Modernization Act 3.0.
Phenotypic screening identifies drug candidates by directly observing what compounds do to living cells - morphology changes, metabolic shifts, toxicity signals, barrier integrity, functional responses - rather than targeting a single molecular pathway. When this methodology deploys on organ-on-chip platforms, you get physiologically relevant human tissue under perfusion flow, mechanical forces, and multi-cell-type architecture that static well plates cannot replicate.
PhenoChip names this convergence: the screening application running on the hardware platform. Every organ-on-chip company builds the noun. PhenoChip is the verb - what you do with it. This is the workflow layer that transforms microphysiological hardware into an FDA 3.0-compliant drug discovery tool.
Observe what drugs do. Measure morphology, viability, function, and toxicity across cellular systems without a known target. The $2.5B methodology growing at 11.5% CAGR - rediscovering the power of watching biology respond.
Build living human tissue. Microfluidic channels with human cells under perfusion, mechanical stretch, and physiological gradients. The microphysiological system that outperforms animal models by every published metric.
Phenotypic drug screening on microphysiological platforms. The FDA 3.0-compliant workflow that every chip company needs - and every pharma pipeline will require.
Human cells seeded into microfluidic chips. iPSC-derived, patient-derived, or primary. Multi-cell co-culture under perfusion flow.
Drug libraries applied to living tissue. Thousands screened in parallel across 64 - 384 chip arrays using standard automation.
High-content imaging captures morphology, viability, barrier integrity, metabolism. AI extracts deep phenotypic signatures.
Compounds scored for efficacy vs. toxicity. Phenotypic profiling reveals mechanism-agnostic hits target screens miss.
Nonclinical data submitted to FDA. ISTAND-qualified platforms accepted as primary evidence for IND applications.
Over 4,000 micro-vessels grown under perfusion. Phenotypic screen yielded 53 anti-angiogenic hits - 44 previously unknown targets that molecular screening would never find.
Largest head-to-head study. Human liver chips outperformed animal models. First organ-chip accepted into FDA's ISTAND program. Moderna now uses it for LNP safety assessment.
Recursion-Exscientia merger created the end-to-end phenomics-to-chemistry platform. AI extracts deep phenotypic signatures without prior biological hypothesis.
Launched SLAS 2026. Automated confocal imaging for 3D tissue and organ-on-chip platforms. Quantitative phenotypic profiling at drug discovery throughput.
Integrating patient organoids with chip technology enables personalized phenotypic drug screening - retaining individual genetic and phenotypic characteristics for precision oncology.
Drug evaluation on chips generates massive imaging datasets. Neural networks extract phenotypic features humans cannot categorize - real-time mechanism-of-action from tissue response.
Traditional phenotypic screening runs on flat 2D well plates - no perfusion, no mechanical forces, no tissue architecture. Over 90% of phenotypic hits from flat plates fail clinical translation. The biology isn't real enough to screen against.
Organ-on-chip companies build beautiful human tissue models, but the readout layer - how you systematically interrogate drug effects at scale - is the phenotypic screening application. Hardware without screening is a demonstration, not a tool.
Chip-based phenotypic screening solves both problems simultaneously. Physiologically relevant tissue interrogated by mechanism-agnostic observation. This is FDA 3.0 compliance in practice - the verb and the noun, unified.
The category-defining domain at the intersection of phenotypic drug discovery and organ-on-chip technology. Part of the Patient Analog biotech domain portfolio.
Acquisition InquiriesThis premium domain is available for acquisition. Perfect for companies, startups, or investors in this space.
Submit your inquiry below and we'll respond within 24 hours.